Arcus Biosciences Inc (RCUS)
Pretax margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -301,000 | -288,000 | -284,000 | -277,000 | -266,000 | 82,538 | 69,563 | 60,593 | 55,000 | -278,391 | -198,594 | -167,698 | -122,858 | -87,603 | -111,777 | -94,793 | -84,710 | -80,407 | -68,867 | -54,310 |
| Revenue (ttm) | US$ in thousands | 117,000 | 119,355 | 121,236 | 118,995 | 112,000 | 433,144 | 408,724 | 399,137 | 398,304 | 53,292 | 108,361 | 92,939 | 77,517 | 77,780 | 15,000 | 15,000 | 15,000 | 6,812 | 9,353 | 8,853 |
| Pretax margin | -257.26% | -241.30% | -234.25% | -232.78% | -237.50% | 19.06% | 17.02% | 15.18% | 13.81% | -522.39% | -183.27% | -180.44% | -158.49% | -112.63% | -745.18% | -631.95% | -564.73% | -1,180.37% | -736.31% | -613.46% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-301,000K ÷ $117,000K
= -257.26%
The pretax margin of Arcus Biosciences Inc has exhibited significant fluctuations over the past eight quarters. The pretax margin was consistently negative in the last four quarters, reaching its lowest point in Q4 2023 at -257.26%. This indicates that the company's expenses exceeded its revenues before accounting for taxes during this period.
In contrast, during Q3 and Q4 2022, the company reported positive pretax margins of 19.09% and 17.03% respectively, suggesting that Arcus Biosciences was able to generate profits before tax expenses during these quarters.
Overall, the pretax margin trend indicates a recent deterioration in the company's financial performance, as evidenced by the consistent negative margins in the most recent quarters compared to the positive margins reported in the same quarters a year ago. This suggests that Arcus Biosciences may be facing challenges in managing its operating expenses relative to its revenue generation.
Peer comparison
Dec 31, 2023